Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Vanda Pharmaceuticals Inc. (VNDA)

Vanda Q3 revenue rises 24% to $69.8 million; 2026 revenue guidance above $240 million

Positive Impact 4 of 5 earnings Written later

Vanda Pharmaceuticals reported third-quarter 2026 total net product sales of $69.8 million, up 24% from a year earlier and 38% from the second quarter, and updated its 2026 guidance to total revenue of greater than $240 million. The company still posted a net loss of $22.6 million, or $0.37 per diluted share, though that was roughly flat with the year-earlier loss and well below the $62.5 million second-quarter loss.

Key points

  • Q3 2026 total net product sales were $69.8 million, up 24% from $56.3 million in Q3 2025 and up 38% from $50.5 million in Q2 2026.
  • Q3 2026 net loss was $22.6 million (diluted loss per share $0.37), compared with a net loss of $22.6 million ($0.38 per share) in Q3 2025.
  • Total operating expenses were $93.3 million, down 18% from $114.3 million in Q2 2026.
  • Cash, cash equivalents and marketable securities totaled $140.5 million as of September 30, 2026, a decrease of $29.5 million in the quarter.

The filing

CompanyVanda Pharmaceuticals Inc. (VNDA)
Form8-K, current report
Filed with the SECOct 28, 2026, 4:07 PM ET
Accession number0001628280-26-067886

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.